ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FLGT Fulgent Genetics Inc

18.51
-0.08 (-0.43%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Fulgent Genetics Inc NASDAQ:FLGT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.08 -0.43% 18.51 18.16 18.79 18.88 18.30 18.60 213,130 22:00:00

Fulgent to Participate in Upcoming Conferences

05/11/2024 1:00pm

Business Wire


Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more Fulgent Genetics Charts.

Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences:

  • UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time
  • Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 11:30 AM Eastern Time

Live webcasts of the sessions will be available on the Investor Relations section of the Fulgent website at ir.fulgentgenetics.com. Replay of the webcasts will be accessible at the same location beginning approximately one hour following the completion of the event.

About Fulgent

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

Investor Relations Contact: The Blueshirt Group Melanie Solomon, melanie@blueshirtgroup.com

1 Year Fulgent Genetics Chart

1 Year Fulgent Genetics Chart

1 Month Fulgent Genetics Chart

1 Month Fulgent Genetics Chart

Your Recent History

Delayed Upgrade Clock